DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ACCRETION PHARMA LIMITED (ACCPL) share price today?

ACCRETION PHARMA LIMITED (ACCPL) is trading at ₹165.65 on the NSE, down 0.21% on the day. Source: DocStoX.

What is the PE ratio of ACCRETION PHARMA LIMITED?

ACCRETION PHARMA LIMITED has a price-to-earnings (PE) ratio of 19.9 in the Healthcare sector.

What is the market capitalisation of ACCRETION PHARMA LIMITED?

ACCRETION PHARMA LIMITED has a market capitalisation of approximately ₹0 crore.

ACCRETION PHARMA LIMITED

ACCPL·NSE·Healthcare

₹165.65▼ -0.35 (-0.21%)

Healthcare · Pharmaceuticals

High-quality returns — 28% on equity

Day₹165.50

₹168.95

52W₹54

₹17195%

Open

₹168.95

High

₹168.95

Low

₹165.50

Prev Close

₹166.00

Volume

38.4K

VWAP

₹167.73

Snapshot

Key fundamentals

Market Cap

₹0 Cr

P/E Ratio

19.93Fair

P/B Ratio

3.27

EPS

₹8.31

Book Value

₹49.21

ROE

27.60%Strong

ROCE

46.36%Efficient

Dividend Yield

0.00%

Debt / Equity

0.23Low

Face Value

₹10.00

52W High

₹171.15

52W Low

₹53.80

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

Narrow moatHigh uncertainty

Fair value estimate

₹170

▲ 2.8%upside

Trading at ₹166 — 3% below our estimate

BearFair valueBull

₹96₹170₹196

/100

Business quality — Solid

Growth 58Profitability 77Efficiency 50Valuation 82

Plain English

Our view

High-quality returns — 28% on equity
Low debt relative to equity
Fundamental red flags (Piotroski 1/9)

Strengths

Low debt relative to equity
Strong returns on equity (28%)
Capital is working hard (ROCE 46%)
Revenue compounding 16% over 3 years

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

44% ROE fading to 12% over ~10 yrs, on ₹49 book

₹191

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹96

Analyst target

No analyst coverage

—

Blended fair value₹170

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (28%)
Capital is working hard (ROCE 46%)
Revenue compounding 16% over 3 years
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

19.9Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

27.6%Strong

Above 15% is considered healthy for Indian equities

ROCE

46.4%Efficient

Above 18% means capital is working hard

Debt/Eq

0.23Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

—

P/B

3.27

EPS

₹8.31

Div Yield

—

What changed

Recent changes

Domestic institutions+2.8% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 19.9×

Growth

Strong

+45% rev CAGR

Profitability

Excellent

27.6% ROE

Financial health

Rock solid

D/E 0.23

Momentum

N/A

No technicals

Today

Trading activity

Delivery %100.0%

Turnover₹64.41L Cr

Trades11

VWAP₹167.73

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+45.0%

—

10Y

—

Profit

+359.0%

—

10Y

—

EPS

—

10Y

—

Profile

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 35.3%

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company might be capitalizing the interest cost

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Domestic institutions added 2.76 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

74%

Promoter

Promoters

73.5%0.00

Public

23.7%-2.76

FII / FPI

0.0%0.00

DII

2.8%+2.76

Quarterly trend

Ownership over time

Q1 FY27

Promoter73.52%

DII2.76%

Public23.72%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.[1]